Patients who went through the SEE program in Michigan were more likely to stick to their drug regimen and reported less ...

Glaucoma medication adherence and glaucoma-related distress were both improved when patients used the Support, Educate, Empower (SEE) glaucoma coaching program vs the standard written education ...

Enrollment completion in the OCU400 Phase 3 clinical trial combined with positive 3-year data from the Phase 1/2 study are important accomplishments in the Company’s plan to begin bringing this ...

Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized by progressive cognitive decline and ...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) outlined late-stage clinical progress for its lead retinal candidate DURAVYU and ...

Thank you, and thank you all for joining us on today's conference call to discuss EyePoint Pharmaceuticals, Inc.'s Fourth Quarter and Full Year 2025 financial results and recent corporate developments ...

Visiting students can Apply for the summer term. For better or worse humanity is heading down the virtual rabbit hole. We’re ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the three months and full ...

Alzheimer disease (AD) is the most common cause of dementia and one of the leading causes of death in adults age 65 y or ...

Amyloid PET has become a pivotal imaging biomarker for Alzheimer disease (AD), enabling in vivo detection and quantification of β-amyloid deposition. However, variability in quantitative measurements ...